Evolus to Present at the Inaugural Aesthetics Innovation Summit and ASAPS’ The Aesthetic Meeting
April 23 2018 - 7:30AM
Evolus, Inc. (NASDAQ:EOLS) (“Evolus”), a lifestyle aesthetics
company focused on delivering advanced aesthetic procedures and
treatments to physicians and consumers, today announced it will
present during the inaugural Aesthetics Innovation Summit (AIS) on
April 25 and at The Aesthetic Meeting, hosted by The American
Society of Aesthetic Plastic Surgery (ASAPS), taking place April
26-May 1. Both meetings will be held in New York, NY.
In invitation-only panel presentations and on
the scientific podium, Evolus executives will discuss the latest
clinical research and the state of the neurotoxin industry, while
highlighting the Company’s investigational neurotoxin DWP-450,
(prabotulinumtoxinA), a 900 kilodalton (kDa) neuromodulator for the
treatment of adult subjects with moderate to severe glabellar
lines, also known as "frown lines.”
Murthy Simhambhatla, Ph.D., President and Chief
Executive Officer of Evolus, commented, “The aesthetic neurotoxin
industry has approached a major inflection point, with total sales
of $945M in the U.S. in 20171 and an increasingly dynamic
comeptitive landscape. At Evolus, we are creating an aesthetic
platform for a new age to address a large and growing market.
Directly ahead of ASAPS, the inaugural Aesthetic Innovation Summit
will provide insight into the current state of the industry. We
look forward to providing insight into our DWP-450 product
candidate.”
“Our Phase III EVB-003 head-to-head comparative
trial in the EU and Canada demonstrates that DWP-450 clearly met
its primary endpoint at Day 30 in subjects with moderate to severe
glabellar lines compared to onabotulinumtoxinA (Botox®),” added Rui
Avelar, M.D., Chief Medical Officer of Evolus. “We look forward to
presenting these results during The Aesthetic Meeting and further
discussing the merits of DWP-450 as a potential fresh alternative
to other neurotoxins such as Botox during the Hot Topics
Panel.”
Aesthetics Innovation Summit
(AIS)
Panel: Clash of the Toxin Titans: Will the Products That
Dominate Today Determine Tomorrow’s Market Leader?
- Overview: A two-part discussion between
industry and clinical leaders to compare the various aesthetics
offerings and debate the benefits or drawbacks of each
- Date: Wednesday, April 25th at 11:20 am -
12:30 pm EDT
- Featuring: Murthy Simhambhatla, Ph.D., Chief
Executive Officer of Evolus
- Session Moderator: W. Grant Stevens, MD,
FACS
ASAPS’ The Aesthetic
Meeting
Panel: What’s the Difference and Why Should I
Start Using a New Toxin?
- Session: 2018 – The Year of New Toxins: Topical, Short-Acting,
and Something Better Than Botox?
- Chairmen: Jamil Ahmad, MD, Tiffany McCormack, MD and Simeon
Wall, Jr., MD
- Featuring Rui Avelar, M.D., Chief Medical Officer of
Evolus
- Date: Friday, April 27, 2018 at 1:15 – 1:30 pm EDT
Oral Presentation: A Phase III, Multicenter,
Randomized, Double-Blind, Active and Placebo-Controlled, Single
Dose Trial to Demonstrate the Efficacy and Safety of
PrabotulinumtoxinA in Adult Subjects for Treatment of Moderate to
Severe Glabellar Lines
- Date: Sunday, April 29, 2018 at 8:45 – 8:50 am EDT
- Location: Hall E, Room 7 & 8
- Presenter: Dr. Per Heden
Oral Presentation: DWP-450, Purified Botulinum
Toxin Type A, for the Treatment of Moderate-to-Severe Glabellar
Lines in Adult Subjects: Results from a Multi-Center, Open Label,
Repeat Dose, Long Term Exposure, Year Long Phase II Safety
Study
- Date: Monday, April 30, 2018 at 12:00 – 12:05 pm EDT
- Location: Hall E, Room 7 & 8
- Presenter: Dr. Paul Lorenc
1 Marc Goodman, Uy Ear, and Zidong Zhang, “UBS
Specialty Pharmaceuticals Monthly Handbook,” UBS, Apr. 6, 2018, pp
56.
About PrabotulinumtoxinA PrabotulinumtoxinA is
a 900 kDa purified botulinum toxin type A complex. The product
candidate's Biologics License Application (BLA) is currently under
review by the U.S. Food and Drug Administration (FDA). The
product candidate's Marketing Authorization Application (MAA) is
currently also under review by the European Medicines Agency (EMA).
The FDA application is for the temporary improvement in the
appearance of moderate to severe glabellar lines associated with
corrugator and/or procerus muscle activity in adults. The EMA
application is for temporary improvement in the appearance of
moderate to severe vertical lines between the eyebrows seen at
maximum frown (glabellar lines), when the severity has an important
psychological impact in adult patients.
About Evolus, Inc.Evolus is a lifestyle
aesthetics company dedicated to bringing advanced aesthetic
procedures and treatments to physicians and consumers. Evolus
focuses on the self-pay aesthetic market and its lead product
candidate DWP-450 (prabotulinumtoxinA neuromodulator), an
injectable 900 kDa purified botulinum toxin type A complex.
Evolus Contacts:
Media:Kirsten Thomas, The Ruth GroupTel: +1-508-280-6592Email:
kthomas@theruthgroup.com
Investor Contact:Brian Johnston, The Ruth Group Tel: +1
646-536-7028Email: IR@Evolus.com
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Mar 2024 to Apr 2024
Evolus (NASDAQ:EOLS)
Historical Stock Chart
From Apr 2023 to Apr 2024